


May 2014

Corporate Profile

Global Green, Inc. plans to manufacture, market and sell the U.S. patented, exclusively licensed vaccine known as the Salmogenics Vaccine, "Salmogenics™", to combat Salmonella bacteria in poultry and eggs. The vaccine is currently in the final stage of the USDA approval process.

The vaccine is unique in that it is injected directly into the egg, before the chick is hatched, improving the immune system, health and welfare of the chicken, and providing a healthier source of protein for humans.



Salmogenics™ was developed by Nutritional Health Institute Laboratories, LLC (a research affiliate and our majority shareholder).



Domestic Market Opportunity

- Salmonella costs \$3 billion a year in U.S. ¹
- Approximately 1.3 billion humans contract Salmonella annually worldwide, with 2-3 million resulting in death ²
- 1.2 million humans in the U.S. contract Salmonella annually ³
- Approximately 9 billion broiler chickens were produced ⁴
- Almost 37 billion pounds of chicken products will be marketed, measured on ready-to-cook basis ⁵
- Consumer expenditures for chickens total \$70 billion ⁶
- 9.6 billion chickens would benefit from Salmogenics
- The Centers for Disease Control reports that the incidence of Salmonella was the least improved of all foodborne pathogens in terms of achieving national health objective targets for Healthy People 2010.

Sources:

(1) World Health Organization, 2005, (2) Centers for Disease Control, (3) (4) (5) (6) National Chicken Council, 2011

Trial Studies Indicate Use of Salmogenics May Improve Performance of Broilers

- Continuing internal field trial studies show that the use of Salmogenics may increase the performance of broilers, resulting in a healthier protein source and leading to increased profit for the poultry grower. Comparing the experimental or vaccinated broilers over the controls, the studies indicated:
- Improved broiler performance included an average of a .126 pound weight gain, with each bird weighing an average of 5.73 pounds
- Feed conversion improvement of 0.039%
- Mean mortality dropped to 1.406% as compared to the 3.281%, representing a 57% improvement
- Further studies will be conducted to determine the levels of enhancement that Salmogenics could produce in injected broilers.

The Global Green Vaccine Advantage is Significant

Salmogenics Vaccine

- **Fast delivery**
- **Uniform delivery system**
- **Earlier immunity from salmonella**
- **Reduced stress on chickens**
- **Reduced labor costs for inoculation**
- **Improved productivity of chickens**
- **Potential future products for other animals**


September 4, 2013

Global Green, Inc. announced the signing of an agreement with Merial Ltd., the Animal Health Division of Sanofi, to conduct an internal evaluation of Global Green's patented Salmogenics vaccine technology. At the conclusion of the evaluation, Merial has the first option to enter into a license agreement with Global Green for the manufacture, distribution, and sale of the vaccine.

[Read full press release](#)


Foods Associated with Salmonella Outbreaks

Nearly a third of all U.S. salmonella outbreaks between 2004 and 2008 where the source was identified were from poultry, according to the Centers for Disease Control and Prevention. Almost half of all salmonella outbreaks could not be linked to a specific food or were linked to multiple foods, according to estimates by the Emerging Pathogens Institute at the University of Florida.




*Includes sprouts, leafy greens, root vegetables, grains and fish, oil and dairy.

U.S. Red Meat and Poultry Production



Source: USDA, February 2010

Organic Poultry Retail Market Sales



Business Strategy

- ✓ Complete final requirements for USDA approval
- ✓ Develop marketing and sales structure
- ✓ Establish Salmogenics as the industry standard
- ✓ Innovate through internal new product development
- ✓ Establish a leadership position in vaccine technology

Officers

Our leadership brings an in-depth understanding of the dynamics and issues necessary to drive our growth.

- Mehran Ghazvini, DC, NMD** - Chairman of the Board and CEO
- Rene Reed, DC, NMD** - Vice-President, Secretary-Treasurer
- Konky Sotomayor, DVM** - Chief Scientist and Vice-President - R&D

Key Investment Highlights

- ✓ Worldwide market opportunity
- ✓ Focused on contributing to human welfare through technology in vaccines and other nutraceuticals
- ✓ Experienced management team
- ✓ Proprietary patent positions
- ✓ Product expansion potential
- ✓ American-made

Company Website
www.globalgreeninc.com

Investor Relations Contact
 Pam Lagano
 727.480.3082 • info@globalgreeninc.com

For further detail, please review the Company's S-1 filing with the U. S. Securities and Exchange Commission www.sec.gov. This document contains statements that are considered forward-looking statements intended to be subject to safe harbor provisions under the federal securities laws. These statements are not guarantees of the Corporation's future performance and are subject to risks, uncertainties and other important factors that could cause actual performance to be materially different from what is projected. The Company undertakes no obligation to update or revise the forward-looking statements contained in this Corporate Fact Sheet to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.